X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (11598) 11598
Newsletter (309) 309
Book Chapter (38) 38
Newspaper Article (14) 14
Dissertation (9) 9
Magazine Article (6) 6
Publication (6) 6
Conference Proceeding (5) 5
Reference (4) 4
Streaming Video (3) 3
Book / eBook (2) 2
Book Review (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
gefitinib (10829) 10829
humans (7436) 7436
oncology (6312) 6312
female (3852) 3852
mutation (3480) 3480
male (3418) 3418
lung neoplasms - drug therapy (3374) 3374
erlotinib (3255) 3255
chemotherapy (3220) 3220
cancer (3128) 3128
lung cancer (3021) 3021
middle aged (2967) 2967
lung neoplasms - genetics (2830) 2830
aged (2814) 2814
carcinoma, non-small-cell lung - drug therapy (2780) 2780
egfr (2385) 2385
lung neoplasms - pathology (2321) 2321
receptor, epidermal growth factor - genetics (2268) 2268
lung cancer, non-small cell (2263) 2263
epidermal growth factor (2252) 2252
adult (2061) 2061
carcinoma, non-small-cell lung - genetics (2029) 2029
cell lung-cancer (1890) 1890
mutations (1871) 1871
growth-factor receptor (1864) 1864
antineoplastic agents - therapeutic use (1809) 1809
adenocarcinoma (1801) 1801
receptor, epidermal growth factor - antagonists & inhibitors (1676) 1676
non-small cell lung cancer (1658) 1658
carcinoma, non-small-cell lung - pathology (1602) 1602
quinazolines - therapeutic use (1586) 1586
cell line, tumor (1577) 1577
care and treatment (1528) 1528
respiratory system (1514) 1514
protein kinase inhibitors - therapeutic use (1482) 1482
aged, 80 and over (1480) 1480
research (1464) 1464
genetic aspects (1370) 1370
epidermal growth factor receptor (1353) 1353
tumors (1334) 1334
acquired-resistance (1316) 1316
tyrosine (1294) 1294
open-label (1255) 1255
animals (1240) 1240
treatment outcome (1236) 1236
therapy (1224) 1224
survival (1208) 1208
expression (1189) 1189
tyrosine kinase inhibitors (1177) 1177
prognosis (1170) 1170
quinazolines - pharmacology (1147) 1147
resistance (1146) 1146
antineoplastic agents - pharmacology (1142) 1142
tyrosine kinase inhibitor (1133) 1133
respiratory tract diseases (1127) 1127
kinases (1101) 1101
analysis (1081) 1081
receptor, epidermal growth factor - metabolism (1059) 1059
protein kinase inhibitors - pharmacology (990) 990
egfr mutations (983) 983
erlotinib hydrochloride (974) 974
epidermal growth factor receptors (946) 946
nsclc (941) 941
cancer therapies (933) 933
pharmacology & pharmacy (926) 926
1st-line treatment (905) 905
erbb receptors - genetics (904) 904
adenocarcinoma - genetics (902) 902
lung neoplasms - metabolism (875) 875
metastasis (866) 866
lung-cancer (853) 853
apoptosis (842) 842
neoplasm staging (840) 840
mice (835) 835
lung neoplasms - mortality (822) 822
health aspects (805) 805
sensitivity (782) 782
growth-factor-receptor (781) 781
antineoplastic combined chemotherapy protocols - therapeutic use (755) 755
quinazolines - administration & dosage (745) 745
retrospective studies (735) 735
hematology, oncology and palliative medicine (733) 733
adenocarcinoma - drug therapy (719) 719
disease-free survival (717) 717
egfr mutation (716) 716
cell biology (709) 709
patients (705) 705
trial (690) 690
non-small cell lung carcinoma (680) 680
carcinoma, non-small-cell lung - mortality (666) 666
adenocarcinoma - pathology (654) 654
drug therapy (653) 653
drug resistance, neoplasm (640) 640
multicenter (622) 622
signal transduction (616) 616
drug resistance (614) 614
mutation - genetics (611) 611
non-small-cell lung cancer (611) 611
proteins (607) 607
carcinoma, non-small-cell lung - metabolism (599) 599
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (11642) 11642
French (106) 106
Chinese (103) 103
Japanese (99) 99
German (47) 47
Korean (44) 44
Spanish (23) 23
Czech (6) 6
Polish (6) 6
Russian (5) 5
Italian (4) 4
Portuguese (4) 4
Turkish (2) 2
Hungarian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Thoracic Oncology, ISSN 1556-0864, 12/2017, Volume 12, Issue 12, pp. e208 - e210
Journal Article
Clinical cancer research, ISSN 1557-3265, 2013, Volume 19, Issue 8, pp. 2240 - 2247
Journal Article
Annals of Oncology, ISSN 0923-7534, 2/2009, Volume 20, Issue 2, pp. 298 - 304
Journal Article
Journal Article
Cancer chemotherapy and pharmacology, ISSN 1432-0843, 2019, Volume 83, Issue 5, pp. 849 - 858
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2009, Volume 361, Issue 10, pp. 947 - 957
This trial compared gefitinib, an inhibitor of the tyrosine kinase of epidermal growth factor (EGFR), with carboplatin plus paclitaxel as initial treatment of... 
CELL LUNG-CANCER | MEDICINE, GENERAL & INTERNAL | FACTOR-RECEPTOR GENE | MULTICENTER | THERAPY | FUNCTIONAL ASSESSMENT | PROSPECTIVE PHASE-II | 1ST-LINE GEFITINIB | EGFR MUTATIONS | TREATED PATIENTS | ERLOTINIB | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Lung Neoplasms - mortality | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Antineoplastic Agents - therapeutic use | Carboplatin - adverse effects | Carboplatin - therapeutic use | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Female | Adenocarcinoma - genetics | Lung Neoplasms - genetics | Kaplan-Meier Estimate | Proportional Hazards Models | Paclitaxel - adverse effects | Adenocarcinoma - drug therapy | Paclitaxel - therapeutic use | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Quinazolines - therapeutic use | Quinazolines - adverse effects | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Adenocarcinoma - mortality | Care and treatment | Dosage and administration | Nonsmokers | Gefitinib | Health aspects | Lung cancer | Chemotherapy | Pharmaceutical industry | Ovarian cancer | Index Medicus | Abridged Index Medicus
Journal Article
Indian Journal of Medical Research, ISSN 0971-5916, 1/2019, Volume 150, Issue 1, pp. 67 - 72
Background & objectives: Tyrosine kinase inhibitors (TKIs) targeting the epidermal growth factor receptor (EGFR) have been evaluated in patients with advanced... 
MEDICINE, RESEARCH & EXPERIMENTAL | MEDICINE, GENERAL & INTERNAL | GUIDELINES | MUTATION | IMMUNOLOGY | CANCER | EPIDEMIOLOGY | Humans | Middle Aged | ErbB Receptors - genetics | Male | Drug-Related Side Effects and Adverse Reactions - pathology | Erlotinib Hydrochloride - economics | Adult | Female | Carcinoma, Non-Small-Cell Lung - pathology | ErbB Receptors - antagonists & inhibitors | Protein Kinase Inhibitors - economics | Carcinoma, Non-Small-Cell Lung - genetics | Erlotinib Hydrochloride - administration & dosage | Kaplan-Meier Estimate | Gefitinib - economics | Drug-Related Side Effects and Adverse Reactions - epidemiology | Carcinoma, Non-Small-Cell Lung - economics | Protein Kinase Inhibitors - administration & dosage | Mutation - drug effects | Cost-Benefit Analysis | Progression-Free Survival | Aged | Gefitinib - administration & dosage | Carcinoma, Non-Small-Cell Lung - drug therapy | Smoking | Carcinoma | Erlotinib | Patient outcomes | Comparative analysis | Gefitinib | Lung cancer, Non-small cell | Drug therapy | Cancer | Studies | Cellular biology | Lung cancer | Mutation | Females | Patients | Cancer therapies | Drug dosages | Age | Tumors | non-small cell lung cancer | erlotinib | treatment response | gefitinib | pharmacoeconomic analysis | Original | Epidermal growth factor receptor inhibitors | Epidermal growth factor receptor inhibitors - erlotinib - gefitinib - non-small cell lung cancer - pharmacoeconomic analysis - treatment response
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2020, Volume 382, Issue 1, pp. 41 - 50
Osimertinib was compared with standard EGFR blockers among patients with non–small-cell lung cancer with activating mutations in EGFR . The median overall... 
CELL LUNG-CANCER | TRIAL | MEDICINE, GENERAL & INTERNAL | GEFITINIB | PLACEBO | THERAPY | AFATINIB | CHEMOTHERAPY | ERLOTINIB | Lung Neoplasms - drug therapy | Lung Neoplasms - mortality | Humans | Middle Aged | ErbB Receptors - genetics | Male | Antineoplastic Agents - therapeutic use | Protein Kinase Inhibitors - adverse effects | Antineoplastic Agents - adverse effects | Female | Lung Neoplasms - genetics | ErbB Receptors - antagonists & inhibitors | Double-Blind Method | Carcinoma, Non-Small-Cell Lung - genetics | Kaplan-Meier Estimate | Proportional Hazards Models | Gefitinib - therapeutic use | Carcinoma, Non-Small-Cell Lung - mortality | Protein Kinase Inhibitors - therapeutic use | Acrylamides - therapeutic use | Aged | Erlotinib Hydrochloride - therapeutic use | Aniline Compounds - therapeutic use | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Aniline Compounds - adverse effects | Acrylamides - adverse effects | Lung cancer, Non-small cell | Drug therapy | Patient outcomes | Tyrosine | Cell survival | Statistical analysis | Epidermal growth factor receptors | Small cell lung carcinoma | Non-small cell lung carcinoma | Metastasis | Gene deletion | Confidence intervals | Epidermal growth factor | Clonal deletion | Clinical medicine | Gefitinib | Protein-tyrosine kinase | Drug dosages | Cancer | Tumors
Journal Article
Journal of controlled release, ISSN 0168-3659, 2018, Volume 275, pp. 117 - 128
Journal Article